{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:47:00Z","timestamp":1767649620553},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T00:00:00Z","timestamp":1236038400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1007\/s11096-009-9288-x","type":"journal-article","created":{"date-parts":[[2009,3,2]],"date-time":"2009-03-02T10:31:46Z","timestamp":1235989906000},"page":"387-393","source":"Crossref","is-referenced-by-count":21,"title":["Incidence of risk factors for developing hyperkalemia when using ACE inhibitors in cardiovascular diseases"],"prefix":"10.1007","volume":"31","author":[{"given":"Omalhassan","family":"Amir","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yahaya","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Azmi","family":"Sarriff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Awaisu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noorizan","family":"Abd. Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Ismail","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,3]]},"reference":[{"issue":"7","key":"9288_CR1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1524-6175.2004.02866.x","volume":"6","author":"DA Sica","year":"2004","unstructured":"Sica DA. Angiotensin-converting enzyme inhibitors side effects: physiologic and non-physiologic considerations. J Clin Hypertens. 2004;6(7):410\u20136. doi: 10.1111\/j.1524-6175.2004.02866.x .","journal-title":"J Clin Hypertens"},{"issue":"10","key":"9288_CR2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1046\/j.1525-1497.1997.07128.x","volume":"12","author":"MA Perazella","year":"1997","unstructured":"Perazella MA, Mahnensmith RL. Hyperkalemia in the elderly drugs exacerbate impaired potassium homeostasis. J Gen Intern Med. 1997;12(10):646\u201356. doi: 10.1046\/j.1525-1497.1997.07128.x .","journal-title":"J Gen Intern Med"},{"issue":"5","key":"9288_CR3","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","volume":"160","author":"GL Bakris","year":"2000","unstructured":"Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160(5):685\u201393. doi: 10.1001\/archinte.160.5.685 .","journal-title":"Arch Intern Med"},{"issue":"9","key":"9288_CR4","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1093\/ndt\/gfg295","volume":"18","author":"CS Cruz","year":"2003","unstructured":"Cruz CS, Cruz AA, Marcilio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003;18(9):1814\u20139. doi: 10.1093\/ndt\/gfg295 .","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"9288_CR5","first-page":"902","volume":"78","author":"RALES Investigators","year":"1996","unstructured":"RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study, RALES). Am J Cardiol. 1996;78(6):902\u20137.","journal-title":"Am J Cardiol"},{"issue":"4","key":"9288_CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1046\/j.1365-2710.2003.00491.x","volume":"28","author":"C Anton","year":"2003","unstructured":"Anton C, Cox AR, Watson RDS, Ferner RE. The safety of spironolactone treatment in patients with heart failure. J Clin Pharm Ther. 2003;28(4):285\u20137. doi: 10.1046\/j.1365-2710.2003.00491.x .","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"9288_CR7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMra035279","volume":"351","author":"B Palmer","year":"2004","unstructured":"Palmer B. Managing hyperkalemia caused by inhibitors of the renin\u2013angiotensin\u2013aldosterone system. N Engl J Med. 2004;351(6):585\u201392. doi: 10.1056\/NEJMra035279 .","journal-title":"N Engl J Med"},{"issue":"6","key":"9288_CR8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1111\/j.1365-2710.2005.00694.x","volume":"30","author":"M Saito","year":"2005","unstructured":"Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther. 2005;30(6):603\u201310. doi: 10.1111\/j.1365-2710.2005.00694.x .","journal-title":"J Clin Pharm Ther"},{"issue":"6","key":"9288_CR9","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med. 2004;351(6):543\u201351. doi: 10.1056\/NEJMoa040135 .","journal-title":"N Engl J Med"},{"issue":"7407","key":"9288_CR10","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/bmj.327.7407.147","volume":"327","author":"E Wrenger","year":"2003","unstructured":"Wrenger E, Muller R, Moesenthin M, Welte T, Frolich JC, Neumann KH. Interaction of spironolactone with ACE inhibitors or angiotensin receptor blockers: analysis of 44 cases. BMJ. 2003;327(7407):147\u20139. doi: 10.1136\/bmj.327.7407.147 .","journal-title":"BMJ"},{"issue":"4","key":"9288_CR11","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cardfail.2003.10.012","volume":"10","author":"M Svensson","year":"2004","unstructured":"Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10(4):297\u2013303. doi: 10.1016\/j.cardfail.2003.10.012 .","journal-title":"J Card Fail"},{"issue":"7","key":"9288_CR12","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2710.2005.00638.x","volume":"30","author":"FH Ramadan","year":"2005","unstructured":"Ramadan FH, Masoodi N, El-Solh AA. Clinical factors associated with hyperkalemia in patients with congestive heart failure. J Clin Pharm Ther. 2005;30(7):233\u20139. doi: 10.1111\/j.1365-2710.2005.00638.x .","journal-title":"J Clin Pharm Ther"},{"key":"9288_CR13","unstructured":"Chan LN, Horn JR. Management of metabolic drug interactions. In: Carter BL, Lake KD, Raebel MA, Bertch KE, Israel MK, Jermain DM, et\u00a0al., editors. Pharmacotherapy Self-Assessment Program (PSAP). 3rd ed. Module 8. USA: ACCP; 2000. p. 102."},{"key":"9288_CR14","volume-title":"Managing clinically important drug interactions","author":"PD Hansten","year":"2005","unstructured":"Hansten PD, Horn JR. Managing clinically important drug interactions. USA: Wolter Kluwer Health, Inc; 2005."},{"key":"9288_CR15","volume-title":"Drug information handbook international","author":"CF Lacy","year":"2006","unstructured":"Lacy CF, Armstrong LL, Goldman MP, Lance LL. Drug information handbook international. 14th ed. Hudson, Ohlo: Lexi-Comp Inc; 2006.","edition":"14"},{"key":"9288_CR16","volume-title":"Britain, R. P. S. O. G","author":"British National Formulary (BNF)","year":"2007","unstructured":"British National Formulary (BNF). Britain, R. P. S. O. G. 54th ed. London: BMJ Publishing Group Ltd and RPS Publishing; 2007.","edition":"54"},{"key":"9288_CR17","first-page":"208","volume-title":"Discovering statistics using SPSS","author":"A Field","year":"2005","unstructured":"Field A. Discovering statistics using SPSS. London: SAGE Publications Ltd; 2005. p. 208."},{"issue":"12","key":"9288_CR18","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.2105\/AJPH.81.12.1630","volume":"81","author":"DW Hosmer","year":"1991","unstructured":"Hosmer DW, Taber S, Lemeshow S. The importance of assessing the fit of logistic regression models: a case study. Am J Public Health. 1991;81(12):1630\u20135.","journal-title":"Am J Public Health"},{"key":"9288_CR19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S0002-9149(02)02581-X","volume":"90","author":"CI Obialo","year":"2002","unstructured":"Obialo CI, Ofili EO, Mirza T. Hyperkalemia in congestive heart failure patients aged 63 to 85\u00a0years with subclinical renal disease. Am J Cardiol. 2002;90:663\u20135. doi: 10.1016\/S0002-9149(02)02581-X .","journal-title":"Am J Cardiol"},{"key":"9288_CR20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.ahj.2004.10.005","volume":"148","author":"KP Tamirisa","year":"2004","unstructured":"Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004;148:971\u20138. doi: 10.1016\/j.ahj.2004.10.005 .","journal-title":"Am Heart J"},{"key":"9288_CR21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archinte.158.1.26","volume":"158","author":"LC Reardon","year":"1998","unstructured":"Reardon LC, Macpherson DS. Hyperkalemia in outpatients using angiotensin-converting enzyme inhibitors: how much should we worry? Arch Intern Med. 1998;158:26\u201332. doi: 10.1001\/archinte.158.1.26 .","journal-title":"Arch Intern Med"},{"key":"9288_CR22","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jacc.2005.06.010","volume":"46","author":"KB Shah","year":"2005","unstructured":"Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005;46:845\u20139. doi: 10.1016\/j.jacc.2005.06.010 .","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"9288_CR23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0002-9343(01)00642-8","volume":"110","author":"H Schepkens","year":"2001","unstructured":"Schepkens H, Vanholder R, Billiouw J, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med. 2001;110(6):438\u201341. doi: 10.1016\/S0002-9343(01)00642-8 .","journal-title":"Am J Med"},{"key":"9288_CR24","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The Effect of spironolactone on morbidity and mortality in patients with severe heart failure (RALES). N Engl J Med. 1999;341:709\u201317. doi: 10.1056\/NEJM199909023411001 .","journal-title":"N Engl J Med"},{"issue":"2","key":"9288_CR25","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1345\/aph.1H520","volume":"41","author":"MA Raebel","year":"2007","unstructured":"Raebel MA, McClure DL, Chan KA. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia? Ann Pharmacother. 2007;41(2):193\u2013200. doi: 10.1345\/aph.1H520 .","journal-title":"Ann Pharmacother"},{"issue":"2","key":"9288_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1023\/A:1007135517950","volume":"32","author":"M Stevens","year":"2000","unstructured":"Stevens M, Dunlay R. Hyperkalemia in hospitalized patients. Int Urol Nephrol. 2000;32(2):177\u201380. doi: 10.1023\/A:1007135517950 .","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"9288_CR27","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2006.05.030","volume":"152","author":"S Denus De","year":"2006","unstructured":"De Denus S, Tardif J, White M, Bourassa MG, Racine N, Levesque S, et al. Quantification of the risk and predictors of hyperkalemia in patients with left ventricular dysfunction: a retrospective analysis of the studies of left ventricular dysfunction (SOLVD) trials. Am Heart J. 2006;152(4):705\u201312. doi: 10.1016\/j.ahj.2006.05.030 .","journal-title":"Am Heart J"},{"key":"9288_CR28","unstructured":"Horn H. Hyperkalemia due to drug interactions. Pharm Times. 2004; www.hanstenandhorn.com . Accessed 28 Aug 2008."},{"issue":"1","key":"9288_CR29","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","volume":"57","author":"AA Mangoni","year":"2003","unstructured":"Mangoni AA, Jackson SHD. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol. 2003;57(1):6\u201314. doi: 10.1046\/j.1365-2125.2003.02007.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"21","key":"9288_CR30","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1001\/archinte.159.21.2553","volume":"159","author":"DW Bates","year":"1999","unstructured":"Bates DW, Miller EB, Cullen DJ, Burdick L, Williams L, Laird N, et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med. 1999;159(21):2553\u201360. doi: 10.1001\/archinte.159.21.2553 .","journal-title":"Arch Intern Med"},{"issue":"9","key":"9288_CR31","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00228-005-0978-6","volume":"61","author":"G Bente","year":"2005","unstructured":"Bente G, Stig EA, Kim D. Drug-drug interactions among recently hospitalised patients\u2014frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61(9):675\u201381. doi: 10.1007\/s00228-005-0978-6 .","journal-title":"Eur J Clin Pharmacol"},{"key":"9288_CR32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/bmj.282.6258.125","volume":"282","author":"L Ramsay","year":"1981","unstructured":"Ramsay L, Tucker GT. Drugs and the elderly. BMJ. 1981;282:125\u20137.","journal-title":"BMJ"},{"issue":"1","key":"9288_CR33","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0167-4943(01)00214-X","volume":"35","author":"JV Butler","year":"2002","unstructured":"Butler JV, McAvoy H, McEnroy D, Mulkerrin EC. Spironolactone therapy in older patients\u2014the impact of renal dysfunction. Arch Gerontol Geriatr. 2002;35(1):45\u20139. doi: 10.1016\/S0167-4943(01)00214-X .","journal-title":"Arch Gerontol Geriatr"},{"key":"9288_CR34","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0736-4679(02)00434-1","volume":"22","author":"E Hay","year":"2002","unstructured":"Hay E, Derazon H, Bukish N, Katz L, Kruglyakov I, Armoni M. Fatal hyperkalemia related to combined therapy with a COX-2 inhibitor, ACE inhibitor and potassium rich diet. J Emerg Med. 2002;22:349\u201352. doi: 10.1016\/S0736-4679(02)00434-1 .","journal-title":"J Emerg Med"},{"issue":"7","key":"9288_CR35","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/oxfordjournals.aje.a009156","volume":"145","author":"SG Wannamethee","year":"1997","unstructured":"Wannamethee SG, Lever AF, Shaper AG, Whincup PH. Serum potassium, cigarette smoking, and mortality in middle-aged Men. Am J Epidemiol. 1997;145(7):598\u2013606.","journal-title":"Am J Epidemiol"},{"issue":"6","key":"9288_CR36","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/01.ASN.0000018401.82863.FD","volume":"13","author":"SR Orth","year":"2002","unstructured":"Orth SR. Smoking and the kidney. J Am Soc Nephrol. 2002;13(6):1663\u201372. doi: 10.1097\/01.ASN.0000018401.82863.FD .","journal-title":"J Am Soc Nephrol"},{"issue":"6372","key":"9288_CR37","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1136\/bmj.286.6372.1189","volume":"286","author":"B Paice","year":"1983","unstructured":"Paice B, Gray JM, McBride D, Donnelly T, Lawson DH. Hyperkalaemia in patients in hospital. BMJ. 1983;286(6372):1189\u201392.","journal-title":"BMJ"},{"issue":"1","key":"9288_CR38","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00000539-200207000-00006","volume":"95","author":"Y Hu","year":"2002","unstructured":"Hu Y, Carpenter JP, Cheung AT. Life-threatening hyperkalemia: a complication of spironolactone for heart failure in a patient with renal insufficiency. Anesth Analg. 2002;95(1):39\u201341. doi: 10.1097\/00000539-200207000-00006 .","journal-title":"Anesth Analg"},{"key":"9288_CR39","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1681\/ASN.V981535","volume":"9","author":"D Weiner","year":"1998","unstructured":"Weiner D, Wingo C. Hyperkalemia: a potential silent killer. J Am Soc Nephrol. 1998;9:1535\u201343.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"9288_CR40","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.amjmed.2004.09.018","volume":"118","author":"JH Gurwitz","year":"2005","unstructured":"Gurwitz JH, Field TS, Judge J, Rochon P, Harrold LR, Cadoret C, et al. The incidence of adverse drug events in two large academic long-term care facilities. Am J Med. 2005;118(3):251\u20138. doi: 10.1016\/j.amjmed.2004.09.018 .","journal-title":"Am J Med"},{"issue":"3","key":"9288_CR41","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0300-9572(00)00363-4","volume":"49","author":"D Heininger-Rothbucher","year":"2001","unstructured":"Heininger-Rothbucher D, Bischinger S, Ulmer H, Pechlaner C, Speer G, Wiedermann CJ. Incidence and risk of potential adverse drug interactions in the emergency room. Resuscitation. 2001;49(3):283\u20138. doi: 10.1016\/S0300-9572(00)00363-4 .","journal-title":"Resuscitation"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-009-9288-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-009-9288-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-009-9288-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,2]],"date-time":"2021-10-02T14:33:06Z","timestamp":1633185186000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-009-9288-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,3]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["9288"],"URL":"https:\/\/doi.org\/10.1007\/s11096-009-9288-x","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,3]]}}}